Novel CXCL13 transgenic mouse: Inflammation drives pathogenic effect of CXCL13 in experimental myasthenia gravis

Oncotarget

Volumn 7, Issue 7, 2016, Pages 7550-7562

  Weiss, Julia Miriam ^a,b,c,d   Robinet, Marieke ^a,b,c,d   Aricha, Revital ^e   Cufi, Perrine ^a,b,c,d   Villeret, Bérengère ^a,b,c,d   Lantner, Frida ^e   Shachar, Idit ^e   Fuchs, Sara ^e   Souroujon, Miriam C ^f   Berrih Aknin, Sonia ^a,b,c,d   Panse, Rozen Le ^a,b,c,d  

^a Sorbonne Université   (France)

^b CNRS   (France)

^c SORBONNE UNIVERSITÉ   (France)

^d AIM   (France)

^e WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^f OPEN UNIVERSITY OF ISRAEL   (Israel)

Author keywords

Autoimmunity; B cells; Chemokine; CXCL13 CXCR5; Immune response; Immunity; Immunology and microbiology section; Thymus

Indexed keywords

CHOLINERGIC RECEPTOR ANTIBODY; CXCL13 CHEMOKINE; CXCL13 PROTEIN, MOUSE; MESSENGER RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY TITER; ARTICLE; B LYMPHOCYTE; CELL POPULATION; CONTROLLED STUDY; EXPERIMENTAL AUTOIMMUNE MYASTHENIA GRAVIS; FEMALE; GERMINAL CENTER; INFLAMMATION; LYMPHOCYTE MIGRATION; MOLECULAR PATHOLOGY; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; THYMUS; ANIMAL; C57BL MOUSE; CELL CULTURE; COMPLICATION; ENZYME IMMUNOASSAY; EPITHELIUM CELL; FLOW CYTOMETRY; GENETICS; HUMAN; MALE; METABOLISM; MYASTHENIA GRAVIS, AUTOIMMUNE, EXPERIMENTAL; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; THYMUS HYPERPLASIA; TRANSGENIC MOUSE;

ANIMALS; B-LYMPHOCYTES; CELLS, CULTURED; CHEMOKINE CXCL13; EPITHELIAL CELLS; FEMALE; FLOW CYTOMETRY; GERMINAL CENTER; HUMANS; IMMUNOENZYME TECHNIQUES; INFLAMMATION; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MYASTHENIA GRAVIS, AUTOIMMUNE, EXPERIMENTAL; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; THYMUS HYPERPLASIA;

EID: 84958780772     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.6885     Document Type: Article

References (49)

1. Gunn MD, Tangemann K, Tam C, Cyster JG, Rosen SD and Williams LT. A chemokine expressed in lymphoid high endothelial venules promotes the adhesion and chemotaxis of naive T lymphocytes. Proc Natl Acad Sci U S A. 1998; 95:258-263.
2. Legler DF, Loetscher M, Roos RS, Clark-Lewis I, Baggiolini M and Moser B. B cell-attracting chemokine 1, a human CXC chemokine expressed in lymphoid tissues, selectively attracts B lymphocytes via BLR1/CXCR5. J Exp Med. 1998; 187:655-660.
3. Forster R, Mattis AE, Kremmer E, Wolf E, Brem G and Lipp M. A putative chemokine receptor, BLR1, directs B cell migration to defined lymphoid organs and specific anatomic compartments of the spleen. Cell. 1996; 87:1037-1047.
4. Ansel KM, Ngo VN, Hyman PL, Luther SA, Forster R, Sedgwick JD, Browning JL, Lipp M and Cyster JG. A chemokine-driven positive feedback loop organizes lymphoid follicles. Nature. 2000; 406:309-314.
5. Shi K, Hayashida K, Kaneko M, Hashimoto J, Tomita T, Lipsky PE, Yoshikawa H and Ochi T. Lymphoid chemokine B cell-attracting chemokine-1 (CXCL13) is expressed in germinal center of ectopic lymphoid follicles within the synovium of chronic arthritis patients. J Immunol. 2001; 166:650-655.
6. Weiss JM, CufiP, Le Panse R and Berrih-Aknin S. The thymus in autoimmune Myasthenia Gravis: Paradigm for a tertiary lymphoid organ. Rev Neurol (Paris). 2013; 169:640-649.
7. Allen CD, Ansel KM, Low C, Lesley R, Tamamura H, Fujii N and Cyster JG. Germinal center dark and light zone organization is mediated by CXCR4 and CXCR5. Nat Immunol. 2004; 5:943-952.
8. Hardtke S, Ohl L and Forster R. Balanced expression of CXCR5 and CCR7 on follicular T helper cells determines their transient positioning to lymph node follicles and is essential for efficient B-cell help. Blood. 2005; 106:1924-1931.
9. Barone F, Bombardieri M, Manzo A, Blades MC, Morgan PR, Challacombe SJ, Valesini G and Pitzalis C. Association of CXCL13 and CCL21 expression with the progressive organization of lymphoid-like structures in Sjogren's syndrome. Arthritis Rheum. 2005; 52:1773-1784.
10. Khademi M, Kockum I, Andersson ML, Iacobaeus E, Brundin L, Sellebjerg F, Hillert J, Piehl F and Olsson T. Cerebrospinal fluid CXCL13 in multiple sclerosis: a suggestive prognostic marker for the disease course. Mult Scler. 2011; 17:335-343.
11. Aharonov A, Abramsky O, Tarrab-Hazdai R and Fuchs S. Humoral antibodies to acetylcholine receptor in patients with myasthenia gravis. Lancet. 1975; 2:340-342.
12. Le Panse R, Bismuth J, Cizeron-Clairac G, Weiss JM, CufiP, Dartevelle P, De Rosbo NK and Berrih-Aknin S. Thymic remodeling associated with hyperplasia in myasthenia gravis. Autoimmunity. 2010; 43:1-12.
13. Mesnard-Rouiller L, Bismuth J, Wakkach A, Poea-Guyon S and Berrih-Aknin S. Thymic myoid cells express high levels of muscle genes. J Neuroimmunol. 2004; 148:97-105.
14. Safar D, Berrih-Aknin S and Morel E. In vitro anti-acetylcholine receptor antibody synthesis by myasthenia gravis patient lymphocytes: correlations with thymic histology and thymic epithelial-cell interactions. J Clin Immunol. 1987; 7:225-234.
15. Melms A, Schalke BC, Kirchner T, Muller-Hermelink HK, Albert E and Wekerle H. Thymus in myasthenia gravis. Isolation of T-lymphocyte lines specific for the nicotinic acetylcholine receptor from thymuses of myasthenic patients. J Clin Invest. 1988; 81:902-908.
16. Berrih-Aknin S, Morel E, Raimond F, Safar D, Gaud C, Binet J, Levasseur P and Bach J. The role of the thymus in myasthenia gravis: immunohistological and immunological studies in 115 cases. Ann N Y Acad Sci. 1987; 505:50-70.
17. Méraouna A, Cizeron-Clairac G, Le Panse R, Bismuth J, Truffault F, Talaksen C and Berrih-Aknin S. The chemokine CXCL13 is a key molecule in autoimmune Myasthenia Gravis. Blood. 2006; 108:432-440.
18. Le Panse R, Cizeron-Clairac G, Bismuth J and Berrih-Aknin S. Microarrays reveal distinct gene signatures in the thymus of seropositive and seronegative myasthenia gravis patients and the role of CC chemokine ligand 21 in thymic hyperplasia. J Immunol. 2006; 177:7868-7879.
19. Shiao YM, Lee CC, Hsu YH, Huang SF, Lin CY, Li LH, Fann CS, Tsai CY, Tsai SF and Chiu HC. Ectopic and high CXCL13 chemokine expression in myasthenia gravis with thymic lymphoid hyperplasia. J Neuroimmunol. 2010; 221:101-106.
20. Zhang M, Guo J, Li H, Zhou Y, Tian F, Gong L, Wang X, Li Z and Zhang W. Expression of immune molecules CD25 and CXCL13 correlated with clinical severity of myasthenia gravis. J Mol Neurosci. 2013; 50:317-323.
21. Weiss JM, CufiP, Bismuth J, Eymard B, Fadel E, Berrih-Aknin S and Le Panse R. SDF-1/CXCL12 recruits B cells and antigen-presenting cells to the thymus of autoimmune myasthenia gravis patients. Immunobiology. 2013; 218:373-381.
22. Feferman T, Maiti PK, Berrih-Aknin S, Bismuth J, Bidault J, Fuchs S and Souroujon MC. Overexpression of IFN-induced protein 10 and its receptor CXCR3 in myasthenia gravis. J Immunol. 2005; 174:5324-5331.
23. Berrih-Aknin S, Ruhlmann N, Bismuth J, Cizeron-Clairac G, Zelman E, Shachar I, Dartevelle P, de Rosbo NK and Le Panse R. CCL21 overexpressed on lymphatic vessels drives thymic hyperplasia in myasthenia. Ann Neurol. 2009; 66:521-531.
24. CufiP, Dragin N, Weiss JM, Martinez-Martinez P, De Baets MH, Roussin R, Fadel E, Berrih-Aknin S and Le Panse R. Implication of double-stranded RNA signaling in the etiology of autoimmune myasthenia gravis. Ann Neurol. 2013; 73:281-293.
25. CufiP, Dragin N, Ruhlmann N, Weiss JM, Fadel E, Serraf A, Berrih-Aknin S and Le Panse R. Central role of interferon-beta in thymic events leading to myasthenia gravis. J Autoimmun. 2014.
26. Fuchs S, Nevo D, Tarrab-Hazdai R and Yaar I. Strain differences in the autoimmune response of mice to acetylcholine receptors. Nature. 1976; 263:329-330.
27. Meinl E, Klinkert WE and Wekerle H. The thymus in myasthenia gravis. Changes typical for the human disease are absent in experimental autoimmune myasthenia gravis of the Lewis rat. Am J Pathol. 1991; 139:995-1008.
28. Tuzun E, Berrih-Aknin S, Brenner T, Kusner LL, Le Panse R, Yang H, Tzartos S and Christadoss P. Guidelines for standard preclinical experiments in the mouse model of myasthenia gravis induced by acetylcholine receptor immunization. Exp Neurol. 2015.
29. Kramer JM, Klimatcheva E and Rothstein TL. CXCL13 is elevated in Sjogren's syndrome in mice and humans and is implicated in disease pathogenesis. J Leukoc Biol. 2013; 94:1079-1089.
30. Petrie RJ, Doyle AD and Yamada KM. Random versus directionally persistent cell migration. Nature reviews Molecular cell biology. 2009; 10:538-549.
31. Lira SA, Zalamea P, Heinrich JN, Fuentes ME, Carrasco D, Lewin AC, Barton DS, Durham S and Bravo R. Expression of the chemokine N51/KC in the thymus and epidermis of transgenic mice results in marked infiltration of a single class of inflammatory cells. J Exp Med. 1994; 180:2039-2048.
32. Christopherson KW, 2nd, Campbell JJ and Hromas RA. Transgenic overexpression of the CC chemokine CCL21 disrupts T-cell migration. Blood. 2001; 98:3562-3568.
33. Cedile O, Lobner M, Toft-Hansen H, Frank I, Wlodarczyk A, Irla M and Owens T. Thymic CCL2 influences induction of T-cell tolerance. J Autoimmun. 2014; 55:73-85.
34. Martin AP, Coronel EC, Sano G, Chen SC, Vassileva G, Canasto-Chibuque C, Sedgwick JD, Frenette PS, Lipp M, Furtado GC and Lira SA. A novel model for lymphocytic infiltration of the thyroid gland generated by transgenic expression of the CC chemokine CCL21. J Immunol. 2004; 173:4791-4798.
35. Chen SC, Vassileva G, Kinsley D, Holzmann S, Manfra D, Wiekowski MT, Romani N and Lira SA. Ectopic expression of the murine chemokines CCL21a and CCL21b induces the formation of lymph node-like structures in pancreas, but not skin, of transgenic mice. J Immunol. 2002; 168:1001-1008.
36. Chen SC, Leach MW, Chen Y, Cai XY, Sullivan L, Wiekowski M, Dovey-Hartman BJ, Zlotnik A and Lira SA. Central nervous system inflammation and neurological disease in transgenic mice expressing the CC chemokine CCL21 in oligodendrocytes. J Immunol. 2002; 168:1009-1017.
37. Luther SA, Lopez T, Bai W, Hanahan D and Cyster JG. BLC expression in pancreatic islets causes B cell recruitment and lymphotoxin-dependent lymphoid neogenesis. Immunity. 2000; 12(5):471-481.
38. Marchesi F, Martin AP, Thirunarayanan N, Devany E, Mayer L, Grisotto MG, Furtado GC and Lira SA. CXCL13 expression in the gut promotes accumulation of IL-22-producing lymphoid tissue-inducer cells, and formation of isolated lymphoid follicles. Mucosal immunology. 2009; 2:486-494.
39. Cavalcante P, Serafini B, Rosicarelli B, Maggi L, Barberis M, Antozzi C, Berrih-Aknin S, Bernasconi P, Aloisi F and Mantegazza R. Epstein-Barr virus persistence and reactivation in myasthenia gravis thymus. Ann Neurol. 2010; 67:726-738.
40. Katzman SD and Fowell DJ. Pathogen-imposed skewing of mouse chemokine and cytokine expression at the infected tissue site. J Clin Invest. 2008; 118:801-811.
41. Hodge DL, Reynolds D, Cerban FM, Correa SG, Baez NS, Young HA and Rodriguez-Galan MC. MCP-1/CCR2 interactions direct migration of peripheral B and T lymphocytes to the thymus during acute infectious/inflammatory processes. Eur J Immunol. 2012; 42:2644-2654.
42. Foster GR, Masri SH, David R, Jones M, Datta A, Lombardi G, Runkell L, de Dios C, Sizing I, James MJ and Marelli-Berg FM. IFN-alpha subtypes differentially affect human T cell motility. J Immunol. 2004; 173:1663-1670.
43. Rangel-Moreno J, Moyron-Quiroz JE, Hartson L, Kusser K and Randall TD. Pulmonary expression of CXC chemokine ligand 13, CC chemokine ligand 19, and CC chemokine ligand 21 is essential for local immunity to influenza. Proc Natl Acad Sci U S A. 2007; 104:10577-10582.
44. Rodriguez-Gallego E, Riera-Borrull M, Hernandez-Aguilera A, Marine-Casado R, Rull A, Beltran-Debon R, Luciano-Mateo F, Menendez JA, Vazquez-Martin A, Sirvent JJ, Martin-Paredero V, Corbi AL, Sierra-Filardi E, Aragones G, Garcia-Heredia A, Camps J, et al. Ubiquitous transgenic overexpression of C-C chemokine ligand 2: a model to assess the combined effect of high energy intake and continuous low-grade inflammation. Mediators Inflamm. 2013; 2013:953841.
45. Ploix CC, Noor S, Crane J, Masek K, Carter W, Lo DD, Wilson EH and Carson MJ. CNS-derived CCL21 is both sufficient to drive homeostatic CD4+ T cell proliferation and necessary for efficient CD4+ T cell migration into the CNS parenchyma following Toxoplasma gondii infection. Brain Behav Immun. 2011; 25:883-896.
46. Litsiou E, Semitekolou M, Galani IE, Morianos I, Tsoutsa A, Kara P, Rontogianni D, Bellenis I, Konstantinou M, Potaris K, Andreakos E, Sideras P, Zakynthinos S and Tsoumakidou M. CXCL13 production in B cells via Toll-like receptor/lymphotoxin receptor signaling is involved in lymphoid neogenesis in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2013; 187:1194-1202.
47. Finch DK, Ettinger R, Karnell JL, Herbst R and Sleeman MA. Effects of CXCL13 inhibition on lymphoid follicles in models of autoimmune disease. Eur J Clin Invest. 2013; 43:501-509.
48. Klimatcheva E, Pandina T, Reilly C, Torno S, Bussler H, Scrivens M, Jonason A, Mallow C, Doherty M, Paris M, Smith ES and Zauderer M. CXCL13 antibody for the treatment of autoimmune disorders. BMC Immunol. 2015; 16:6.
49. Aharonov A, Tarrab-Hazdai R, Silman I and Fuchs S. Immunochemical studies on acetylcholine receptor from Torpedo californica. Immunochemistry. 1977; 14:129-137.